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ABSTRACT
Objective: The study objective is to evaluate among the different groups of antihypertensive for their cost-effectiveness and to provide information 
about the effective management of hypertensives both clinically and economically.
Methods: This study involves 81 patients aged 18–80 years on antihypertensive treatment who were enrolled from December to May with daily dose 
calculation. It is performed to analyze cost-effectiveness in the management of clinical condition. Data collection form to be entered with age, sex, food 
habits, occupational status, clinical data, and drugs was used for treatment. Incremental cost-effectiveness ratio is calculated based on the incremental 
cost for “per mmHg” reduction and cost for “per patient” reaching target blood pressure (BP).
Result: Angiotensin receptor blockers (ARBs) show a significant average reduction of systolic BP (SBP) and beta-blockers (BBs) show an average 
reduction of diastolic BP (DBP). Angiotensin-converting enzyme inhibitors (ACEIs) are cost effective in SBP and calcium channel blockers are cost 
effective in maintaining DBP.
Conclusion: ARBs, BBs, and ACEIs show the effective management of hypertensives both clinically and economically.
Keywords: Antihypertensive, Cost-effectiveness, Systolic blood pressure, Diastolic blood pressure.
INTRODUCTION
Hypertension (HTN) also known as high blood pressure (BP) is a 
condition where the BP has persistently raised in the blood vessels. Blood 
is carried to all parts of the body from the heart, and the heart pumps 
blood into the vessels. The force of blood pushing against the walls of 
the arteries is called as BP. If the pressure is high, it is harder to pump 
the blood from the heart [1]. HTN has a multifactorial etiology, which 
combines both environmental and genetic factors [2]. HTN is one of the 
risk factors for the development of all the major cardiovascular diseases 
such as coronary artery disease, peripheral artery disease, stroke, heart 
failure, and renal failure which commonly affect the elderly [3].
Treatment strategies
HTN management has two approaches, which are lifestyle modification 
and add-on drug therapy [4].
Pharmacoeconomics
In health care, an economic evaluation is defined as “a comparative 
analysis of alternative courses of action in terms of both their costs and 
consequences” [5]. It is a branch of health economics that deals with 
both the costs and benefits of the drug therapy applied to the health-
care system [6,7]. However, assessment of clinically obtained data is the 
part of economic evaluation and judgment. The role of new drug therapy 
is based mainly on the clinical evidence of drugs’ harms and benefits [8].
Specific tools in the pharmacoeconomic analysis to allow the 






6. Cost of illness analysis.
Need for pharmacoeconomic analysis in India
In a developing country like India, the total health expenditure is nearly 
85% on drug which is a major financial burden on households. A major 
part of private health care spending in India goes to drug and per capita 
private drug estimates as USD 16. Due to limited resources and high 
cost of drugs, many people in India frequently face a choice buying 
medicines or food or other necessities. Hence, medicines and its costs 
do matter in India [10]. Pharmacoeconomics serves as a link between 
medicine and market economy [7]. Pharmacoeconomics implies the 
application of economic principles to evaluate pharmaceuticals [8]. The 
aim is to maximize health benefit for the community to be delivered 
considering the existing limited financial resources [7].
METHODS
A prospective cross-sectional study includes both genders of age 
between 18 and 80 years and excludes the patients who are pregnant 
and lactating women and patients with any comorbidity such as acute 
emergency hypertensive patients, renal transplant patients, and 
malignancy condition. The study group is categorized into two groups 
which include either monotherapy or combination therapy. Monotherapy 
includes angiotensin receptor blockers (ARBs), angiotensin-converting 
enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), and beta 
blockers (BB). Combination therapy includes ARBs with CCBs or BBs or 
ACEIs. This study was approved by the Institutional Ethics Committee of 
VISTAS with reference number “VISTAS-SPS/IEC/I/2017/07.” Patients 
on antihypertensive treatment were enrolled and studied with daily 
dose calculation. Study was performed to analyze cost-effectiveness in 
the management of clinical condition. Data collection form includes age, 
sex, occupational status, clinical data, and drugs used for treatment. 
Incremental cost-effectiveness ratio is calculated based on the 
incremental cost for “per mmHg” reduction and cost for “per patient” 
reaching target BP. The values were statistically evaluated by daily dose 
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calculation and incremental cost for “per mmHg” reduction and cost for 
“per patient” reaching target BP.
RESULT
Of 81 patients, 41 (50.6%) were male and 40 (49.3%) were female. 
Patients receiving single-drug therapy were 79.01%, combination 
therapies were 17.28%, and triple therapy were 3.71%.
SUMMARY AND CONCLUSION
The aim of the present study was to perform cost-effectiveness analysis 
of antihypertensive drugs in a cardiology outpatient department. 
A total number of 81 patients were enrolled in this study (Table 1). 
Demographic study and cost-effectiveness analysis were performed for 
the patients, and the study has estimated the following results:
•	 Both	genders	are	found	to	be	affected	by	HTN,	with	an	average	age	
in the range of 51–70 years of age and 6–10 years of duration.
•	 Population	within	the	range	of	6–10	years	of	duration	was	found	to	
have increased percentage of obese, smokers, alcoholism, stress, and 
family history.
•	 Population	within	 the	age	group	of	51–70	years	was	 found	 to	be	
non-workers with the increased weight loss (Table 2).
•	 An	increased	number	of	patients	were	treated	effectively	with	single	
drug therapy (Table 3).
•	 ARBs	were	prescribed	mostly	for	single-	drug	therapy.	ARBs	result	
in highest average reduction of systolic BP (SBP).
•	 A	combination	of	ARBs	with	BBs	was	prescribed	mostly	for	two-drug	
combination therapy and CCBs with ARBs has higher SBP average 
reduction.
•	 A	combination	of	ARBs	with	BBs	and	CCBs	was	mostly	prescribed	
for three-drug combination therapy and ARBs with ACEIs and BBs 
has higher average reduction of SBP.
•	 BBs	result	in	higher	average	reduction	of	diastolic	BP	(DBP)	in	single	
drug therapy.
•	 ARBs	with	 CCBs	 show	a	 higher	 reduction	 of	DBP	 in	 two-drug	
combination therapy (Table 4).
•	 ARBs	with	ACEIs	and	BBs	have	a	higher	average	reduction	of	DBP	
(Table 4).
Table 1: Data on patients enrolled for the study
Patient enrolment data
Number of male patients (%) 41 (50.6)
Number of female patients (%) 40 (49.3)
Total number of patients enrolled (%) 81 (100)
Table 2: Social and clinical parameters
Age (in years) 18–30 31–50 51–70 71–80
Duration of treatment  
(in years)
0 1–5 6–10 11–15
BMI 0 25.82 26.19 25.34
Weight gain (%) 0 11.11 28.39 2.46
Weight loss (%) 0 22.21 32.01 3.70
Family history (%) 0 17.28 35.80 1.23
Smoking (%) 0 11.11 17.28 2.46
Alcoholism (%) 0 4.93 9.87 0
Stress (%) 0 16.04 25.92 3.70
Obese (%) 0 11.11 18.51 1.23
Active (%) 0 14.81 11.11 0
Non-worker (%) 0 18.52 24.69 1.23
Pensioner (%) 0 0 24.6 4.93
BMI: Body mass index
Table 3: Therapy provided to selected patients (n=81)
Therapy Percentage of patients received 
treatment (%)
Single-drug therapy 79.01
Two-drug combination therapy 17.28
Three-drug combination therapy 3.71











ARB 7774.5 4.3 100 1808.02 77.74
BB 3978.5 4.74 100 839.34 39.78
ACE 967.25 1 70 967.25 13.78
CCB 854.1 1.22 67 700.08 12.74
ACE+CCB 8336.6 1.7 100 4903.88 83.36
ARB+BB 5551.65 2.82 80 1968.67 69.39
ARB+ACE 3412.75 3.4 100 1003.75 34.12
ARB+CCB 3869.00 5.09 100 760.11 38.69
BB+ACE 5354.55 2.6 100 2059.44 53.54
ARB+CCB+BB 9303.85 0.3 100 31012.83 93.03
ARB+BB+ACE 11,245.65 1.4 100 8032.60 112.45
DBP: Diastolic blood pressure, ARB: Angiotensin receptor blocker, CCB: Calcium channel blocker, ACE: Angiotensin-converting enzyme, BB: Beta-blocker











ARB 7774.5 10.4 84 747.54 92.55
BB 3978.5 9.4 90 423.24 44.20
ACE 967.25 9.5 85 101.81 11.37
CCB 854.1 7 80 122.01 10.67
ACE+CCB 8336.6 7 67 1190.94 124.42
ARB+BB 5551.65 10.5 100 528.72 55.51
ARB+ACE 3412.75 8.6 100 396.83 34.12
ARB+CCB 3869.00 9.2 100 420.54 38.69
BB+ACE 5354.55 8.5 100 629.94 53.54
ARB+CCB+BB 9303.85 7.8 100 1192.80 93.03
ARB+BB+ACE 11,245.65 8.1 100 1388.35 112.45
SBP: Systolic blood pressure, ARB: Angiotensin receptor blocker, CCB: Calcium channel blocker, ACE: Angiotensin-converting enzyme, BB: Beta-blocker
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•	 ARBs	with	BBs	and	CCBs	hold	 the	 lowest	cost	among	 three-drug	
combination therapy.
•	 Cost-effectiveness	of	 anti-HTN	drugs	based	on	 the	 cost/average	
reduction and cost/patients with target BP.
•	 ARBs	with	CCBs	show	a	significant	reduction	in	BP.	ACEIs	show	
cost effective in the reduction per mmHg reduction of SBP. CCBs 
show the cost effective in the reduction per mmHg reduction 
of DBP. CCBs shows the cost effective to maintain the target BP 
(Tables 4 and 5).
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